News Archive

/static/apps/cms/news/1416/Peter Ward 500.jpg

New Antibody Treatment Discovered by Ward Lab Approved by FDA

April 6, 2023 / Research

After several decades of hard work by many scientists at the University of Michigan Medical School and elsewhere, an antibody (anti-C5a) has just been approved by the US FDA for treatment of humans who are septic and have developed lung infections with COVID-19, resulting in severe pulmonary dysfunction requiring external lung support. The antibody, anti-C5a, was originally developed in the Dr. Peter Ward laboratory in the early 2000s. The mAb was shown to dramatically reduce lung infections in polymicrobial sepsis in mice. 

FULL STORY